CDT Equity Inc. has entered into an evaluation agreement with Manoira Corporation to assess the potential of its clinical-stage compounds AZD1656 and AZD5904 for Manoira’s animal healthcare business. The agreement, dated October 22, 2026, stipulates that Manoira will analyze CDT’s assets to determine if they can improve the efficacy, safety, or formulation of Manoira’s upcoming product range. Manoira is currently in the manufacturing and testing phase ahead of its first product launch in the first quarter of 2027.
As consideration for this evaluation, CDT issued 1,347,616 shares of common stock to Manoira. These shares, valued at $0.1447 per share, represent a total payment of $195,000. The transaction was conducted without registration under the Securities Act of 1933, relying on exemptions pursuant to Section 4(a)(2) and Rule 506 of Regulation D.
The agreement also details other equity issuances by CDT on October 22 and 23, 2026. These include 397,374 shares to a service provider for consulting services, 437,779 shares to Sarborg Limited under a securities purchase agreement, and 499,616 shares to Dr. Andrew Regan in lieu of $65,000 severance compensation following his resignation as Chief Executive Officer. Dr. Regan is the beneficial owner of more than five percent of CDT’s outstanding common stock and serves as the sole director of Manoira.
